All News
Novel and Emerging Therapies in Psoriatic Arthritis
Recent advancements in targeted therapies, including selective inhibitors of key inflammatory pathways, offer promising outcomes for patients with active psoriatic arthritis (PsA). At ACR 2024, there have been further developments in novel therapies in PsA.
Read Article
ICYMI: Taking AI Out of AutoImmunity: Predicting disease before it develops
the predictive value of a positive ANA test—especially in the absence of other clinical symptoms—remains a challenge. A positive test often leads to further testing, yet it does not necessarily indicate whether a patient truly has an underlying autoimmune disease. The development of AI and machine learning algorithms presents an opportunity to interpret autoantibody tests and predict autoimmune diseases. Here are three studies looking at this issue.
Read Article
Is Your Practice Up to Date? New Guidelines for SLE Nephritis
Randomized controlled trials (RCTs) drive guidelines; guidelines drive clinical practice. Because updated guidelines lag trials by many years and dissemination of guidelines takes additional time, rheumatologists often practice “behind the data.” The 2024 ACR Guidelines for the Management of SLE Nephritis reaffirmed many of our typical practice patterns, including hydroxychloroquine for all, renin/angiotensin blockade, and favoring mycophenolate mofetil over cyclophosphamide.
Read Article
Aging Gracefully in Managing Rheumatic Diseases
Dr. Mrinalini Dey and Dr. Elena Myasoedova review highlights from a session on aging presented at #ACR24.
https://t.co/tyT5d0JsEG https://t.co/szfDsSuWBx
Dr. John Cush RheumNow ( View Tweet)
NEW ONLINE POSTER: Safety of a JAKi presented at EULAR 2024!
View safety across 15,000 patient-years of data from 11 Phase 3 trials, including adult patients with RA, PsA, AS, and nr-axSpA. This poster is sponsored by AbbVie US Medical Affairs.
https://t.co/gIFWRqOGmD https://t.co/L0YttKihdf
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR24 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty.
Dr. John Cush RheumNow ( View Tweet)
A new score to quantify GCA inflammation?
The treatment paradigm for Giant Cell Arteritis (GCA) has been a binary approach to the presence or absence of vasculitis. When GCA is present, we institute high doses of glucocorticoids for treatment of the inflammatory process. #ACR24… https://t.co/b5H7KOtZPC https://t.co/AvrwHcXI7r
Dr. John Cush RheumNow ( View Tweet)
Up-front Secukinumab in PsA?
We now have an absolute plethora of agents available for use in psoriatic arthritis (PsA). In contrast we have an almost complete lack of understanding of how best to optimise use of these agents – what is the right agent at the right time for the… https://t.co/OAQOutluPe https://t.co/gLfG840DBP
Dr. John Cush RheumNow ( View Tweet)
Gender Differences in SpA
#ACR24 provided its attendees with vast information about disease pathophysiology, diagnosis and treatment covering both clinical and basic sciences. One of the hot topics during the meeting was gender differences in SpA. Three abstracts presented… https://t.co/iEh0s3sIhc https://t.co/SRhz0Uwwwv
Dr. John Cush RheumNow ( View Tweet)
#ACR24 - Day 3 Report
Highlights from Day 3 at ACR24 included the plenary session presentation on Nipocalimab (previously reviewed), but the big highlight was the Lupus Nephritis guideline recommendations.
https://t.co/Dif4EUi30b https://t.co/4hfEJ1ef73
Dr. John Cush RheumNow ( View Tweet)
Health Literacy: the forgotten social determinant of health?
Nine out of ten adults in the USA struggle to understand basic health-related information (1). Across the pond, in the UK, 7.1 million adults read at, or below, the level of a nine-year-old, with 60% unable to… https://t.co/686bWffD2z https://t.co/TFyzgJ3NeL
Dr. John Cush RheumNow ( View Tweet)
JAK inhibitors in GCA?
We have a phase 3 trial in giant cell arteritis back on the opening day plenary stage. The SELECT-GCA study, looking at upadacitinib in GCA, was scheduled to anchor the #ACR24 opening plenary for a reason - it is highly notable and badly needed.… https://t.co/aJ3uao1wD7 https://t.co/6ao2OoODHg
Dr. John Cush RheumNow ( View Tweet)
Highlights in axSpA
Dr. Marina Magrey discusses highlights in axSpA from the first day at #ACR24
https://t.co/LvvmzlXWw7 https://t.co/thf9MiMo32
Dr. John Cush RheumNow ( View Tweet)
ANCA Vasculitis "Eye": Can rituximab help?
Dr. Janet Pope discusses abstract 0726 at #ACR24
https://t.co/KzYcmjon8D https://t.co/KDIi1vJE4P
Dr. John Cush RheumNow ( View Tweet)
RA Treatment Adherence: Is decision making really shared?
Dr. Jonathan Kay interviews Dr. Cécile Gaujoux-Viala about abstract 0360 at #ACR24.
https://t.co/KwXHutfQko https://t.co/bCVM3JrFEz
Dr. John Cush RheumNow ( View Tweet)
Treat-to-Target Improves Fertility in Women with RA
Dr. Richard Conway discusses abstract 1647, presented at #ACR24
https://t.co/vC0CA0lN4M https://t.co/Dfo7iBYwcU
Dr. John Cush RheumNow ( View Tweet)
GLP-1 Agonists Show Promise in Slowing Kidney Disease in Lupus Nephritis
Glucagon-like peptide-1 receptor agonists (GLP-1Ra) have transformed the treatment landscape for type 2 diabetes and obesity. #ACR24
https://t.co/6QqEH8X2VJ https://t.co/Ch2i9zZYii
Dr. John Cush RheumNow ( View Tweet)
ORAL Surveillance - Is Statin Use the Problem/Solution?
The findings from ORAL Surveillance Study have been a dominant conversation at #ACR24, with the seminal findings and subsequent analyses a target of debate.
https://t.co/Nn9KSL4dlv https://t.co/gHPwK35eEd
Dr. John Cush RheumNow ( View Tweet)
#ACR24: What Exactly do JAKs and TYKs Do?
Let me start by confessing something embarrassing: the immune system is just too complex for me to understand. I suspect the onslaught of new drugs with new mechanisms at ACR 2024 may have left many of you feeling similarly.… https://t.co/HkhZJBxDdO https://t.co/xYeSpHS2dD
Dr. John Cush RheumNow ( View Tweet)
Addressing CV Risk in RA: Are we doing enough?
The increased risk of cardiovascular disease in patients with rheumatoid arthritis has long been known (1). #ACR24
https://t.co/dajYuK8rpd https://t.co/2Ds3OZEjUX
Dr. John Cush RheumNow ( View Tweet)